<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F7963F0F-F1A1-4A44-A563-A29028086C5B"><gtr:id>F7963F0F-F1A1-4A44-A563-A29028086C5B</gtr:id><gtr:name>Ingenza Ltd</gtr:name><gtr:address><gtr:line1>Wallace Building</gtr:line1><gtr:line2>Roslin Biocentre</gtr:line2><gtr:line3>Roslin</gtr:line3><gtr:line4>Midlothian</gtr:line4><gtr:postCode>EH25 9PP</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/7801F008-7C77-45E7-90E9-4345B47D138E"><gtr:id>7801F008-7C77-45E7-90E9-4345B47D138E</gtr:id><gtr:name>University of Plymouth</gtr:name><gtr:department>Sch of Biomedical and Healthcare Sci</gtr:department><gtr:address><gtr:line1>Drake Circus</gtr:line1><gtr:line4>Plymouth</gtr:line4><gtr:line5>Devon</gtr:line5><gtr:postCode>PL4 8AA</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7801F008-7C77-45E7-90E9-4345B47D138E"><gtr:id>7801F008-7C77-45E7-90E9-4345B47D138E</gtr:id><gtr:name>University of Plymouth</gtr:name><gtr:address><gtr:line1>Drake Circus</gtr:line1><gtr:line4>Plymouth</gtr:line4><gtr:line5>Devon</gtr:line5><gtr:postCode>PL4 8AA</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:line4>Swindon</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SN2 1ET</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>CO_FUNDER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F7963F0F-F1A1-4A44-A563-A29028086C5B"><gtr:id>F7963F0F-F1A1-4A44-A563-A29028086C5B</gtr:id><gtr:name>Ingenza Ltd</gtr:name><gtr:address><gtr:line1>Wallace Building</gtr:line1><gtr:line2>Roslin Biocentre</gtr:line2><gtr:line3>Roslin</gtr:line3><gtr:line4>Midlothian</gtr:line4><gtr:postCode>EH25 9PP</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/81EDBB09-1DD7-41D5-8A5C-BE1ACE4591F8"><gtr:id>81EDBB09-1DD7-41D5-8A5C-BE1ACE4591F8</gtr:id><gtr:firstName>Mathew</gtr:firstName><gtr:surname>Upton</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FM01830X%2F1"><gtr:id>21297AFA-6093-45FB-BF4D-A972B4727837</gtr:id><gtr:title>Efficient production of first in class antimicrobial therapeutics from an integrated synthetic biology approach</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/M01830X/1</gtr:grantReference><gtr:abstractText>Antibiotic resistant bacteria kill over 25,000 people a year in Europe and threaten a return to a time when minor infections can be fatal and routine surgery poses high risks. With development pipelines empty, there is a critical need for novel therapies to kill antibiotic resistant bacteria and serve as scaffolds for derivatisation, diversification and enhancement of efficacy, which proved successful with drugs like penicillin. Epidermicins are an exciting new class of antimicrobial biologics (ABs) that rapidly kill bacteria, at very low doses and have great potential to prevent or treat bacterial infections including those caused by resistant bacteria. However, the development of the epidermicins is greatly hampered by their very low production in the native host and synthetic production would be prohibitively expensive. This project aims to develop efficient, scalable microbial production systems for epidermicins, enabling their development into a new platform of effective antibiotics.</gtr:abstractText><gtr:technicalSummary>Antibiotic resistant bacteria kill over 25,000 people a year in Europe and threaten a return to a time when minor infections can be fatal and routine surgery poses high risks. With development pipelines empty, there is a critical need for novel therapies to kill antibiotic resistant bacteria and serve as scaffolds for derivatisation, diversification and enhancement of efficacy, which proved successful with drugs like penicillin. Epidermicins are an exciting new class of antimicrobial biologics (ABs) that rapidly kill bacteria, with nanomolar level potency and have great potential to prevent or treat bacterial infections including those caused by resistant bacteria. In recent in vivo trials, a single dose of epidermicin was as effective as 6 doses of the gold standard treatment for nasal MRSA carriage - this is the initial target market for epidermicin. This represents significant competitive advantage over current and developmental agents in this ~$100M per year market. Epdiermicin has a good in vitro profile for use in therapy of dermatological infections, including impetigo, with significantly larger markets.
However, the development of the epidermicins is greatly hampered by their very low production in the native host and synthetic production would be prohibitively expensive. This project aims to use Ingenza's cutting-edge, propriety technology to develop efficient, scalable microbial production systems for epidermicins and other peptides, enabling their development into a new platform of effective antibiotics.</gtr:technicalSummary><gtr:potentialImpactText>As described in proposal submitted to TSB</gtr:potentialImpactText><gtr:fund><gtr:end>2017-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2015-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>218142</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ingenza Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Development of expression system for commercial scale production</gtr:description><gtr:id>EDD0482A-EACE-4F1A-8B59-42AC522C79E0</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>546cd8b5187b20.88635277-1</gtr:outcomeId><gtr:partnerContribution>Ingenza are bringing 14 years of IB expertise to the project to maximise the chance of successfully achieving our target level of expression</gtr:partnerContribution><gtr:piContribution>Ingenza have partnered with us to develop the recombinant expression system for production of epidermicin and related peptides. This work is now supported by a TSB/Innovate UK IBC award (starting April 2015).

My research team will be evaluating the peptides that are produced in the Ingenza expression pipeline.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>BBC radio 4 Today programme interview, 1st October 2015</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>074EF55A-9233-404A-96D0-A2FD8EE19C72</gtr:id><gtr:impact>Radio interview that was picked up by various groups across the UK and resulted in a request from the Chief Medical Officer's office for more information on the work I am doing</gtr:impact><gtr:outcomeId>56e0a3cb0c1685.72072167</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>85000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Capital equipment for AMR research</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Innovate UK</gtr:fundingOrg><gtr:fundingRef>86184-540263</gtr:fundingRef><gtr:id>89D07CEC-DE1B-4D34-AD50-87D832B72A8A</gtr:id><gtr:outcomeId>58adc9b4cbe4c8.16710583</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>We have made developments in the search for new antimicrobials and have established a system for producing epidermicin at a commercially viable scale, the primary aim of the project.</gtr:description><gtr:exploitationPathways>The findings will support additional funding requests to relevant funding bodies</gtr:exploitationPathways><gtr:id>42B6C7B6-2C2C-4665-90E7-BD1106D11C59</gtr:id><gtr:outcomeId>56e0a63d44b010.30264870</gtr:outcomeId><gtr:sectors><gtr:sector>Healthcare,Manufacturing, including Industrial Biotechology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">BB/M01830X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>17F21DBC-4946-4262-AD07-9914F6EA12F7</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Bioengineering</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>F442B6BE-8B89-4C01-8D3B-E8A4D320B672</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Biomolecules &amp; biochemistry</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>2607D197-52EE-40CA-A1D5-A46D18C3F97F</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Microbial sciences</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>18D298A9-FFE3-432F-B077-E3B703272E29</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Biochemical engineering</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>BD108981-2A72-4C45-AAC2-425461EB90BE</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Biomaterials</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>5BA89E2C-27FE-4553-819B-3CE27FC71EC2</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Microbiology</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>9031EBB8-791D-4466-9E80-80F98BCB26E1</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Protein expression</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>